within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02A_AntiadrenergicAgentsCentrallyActing.C02AC01_Clonidine;

model Clonidine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.75,
    Cl = 4.472222222222223e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.0021000000000000003,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 0,
    Vdp = 0.0070999999999999995,
    k12 = 3.694444444444444e-05,
    k21 = 3.694444444444444e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Clonidine</td></tr><tr><td>ATC code:</td><td>C02AC01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.23</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Clonidine is a centrally acting alpha-2 adrenergic agonist commonly used for the treatment of hypertension and attention-deficit hyperactivity disorder (ADHD), and as adjunct therapy in opioid withdrawal and analgesia. It is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>PK parameters reported for healthy adult subjects after single oral administration.</p><h4>References</h4><ol><li><p>Larsson, P, et al., &amp; Anderson, BJ (2011). Oral bioavailability of clonidine in children. <i>Paediatric anaesthesia</i> 21(3) 335–340. DOI:<a href=\"https://doi.org/10.1111/j.1460-9592.2010.03397.x\">10.1111/j.1460-9592.2010.03397.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20735802/\">https://pubmed.ncbi.nlm.nih.gov/20735802</a></p></li><li><p>De Hondt, L, et al., &amp; Tommelein, E (2024). Quantification of ADHD medication in biological fluids of pregnant and breastfeeding women with liquid chromatography: a comprehensive review. <i>Frontiers in public health</i> 12 1437328–None. DOI:<a href=\"https://doi.org/10.3389/fpubh.2024.1437328\">10.3389/fpubh.2024.1437328</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39171321/\">https://pubmed.ncbi.nlm.nih.gov/39171321</a></p></li><li><p>Bienert, A, et al., &amp; Grześkowiak, E (2015). Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. <i>Journal of clinical pharmacology</i> 55(3) 307–316. DOI:<a href=\"https://doi.org/10.1002/jcph.401\">10.1002/jcph.401</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25243731/\">https://pubmed.ncbi.nlm.nih.gov/25243731</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C02AC01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Clonidine;
